Samsung Bioepis' Q1 2025 report shows oncology, ophthalmology, and pegfilgrastim biosimilars have gained significant market share, while immunology, filgrastim, epoetin alfa, and insulin glargine ...

Samsung Bioepis and Teva have entered into a license, development and commercialization agreement for Epysqli ...

Marks the Third Year Since the Launch of the First US Biosimilar Market Report INCHEON, South Korea, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Co., Ltd. today released its First Quarter 2025 Biosimilar ...

INCHEON, South Korea, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. today released its First Quarter 2025 Biosimilar Market Report, marking the eighth edition of the Quarterly ...

New partnerships aim to expand Teva’s biosimilar portfolio and enhance access to high-cost biologics across key markets.

While most of its current revenue comes from the contract manufacturing business, Samsung Biologics aims to increase its exposure in the contract development organization business, which provides a ...

Samsung Bioepis announced on the 12th that it has signed a commercialization partnership agreement with Teva Pharmaceutical Industries to enter the U.S. market with the rare disease treatment ...

Samsung launches online marketplace to boost domestic economy for Lunar New Year Samsung aims to enhance holiday shopping ...

Samsung Biologics has made history by becoming the nation's first biotech company to hit 4 trillion won ($2.78 billion) in ...